Menopausal Hormone Therapy with Estrogen Alone Decreases Breast Cancer Incidence
December 14th 2019Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.
Read More
Arimidex Extends Benefit of Breast Cancer Recurrence Prevention in Postmenopausal Women
December 13th 2019Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
Read More
Adding S-1 to Endocrine Therapy Improves Survival in Japanese Patients with Breast Cancer
December 12th 2019Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.
Read More
Addition of Perjeta to Standard Care Improves Survival in HER2-Positive Early Breast Cancer
December 12th 2019Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.
Read More
Oropharyngeal Cancer Risks Include Number of Sexual Partners, Smoking
December 9th 2017The incidence of human papillomavirus-related oropharyngeal cancer (HPV-OPC) is on the rise. Researchers at Johns Hopkins University assessed survey data to determine whether the risk among the general population is rising as well. Results show that for most people, the risk remains low.
Read More
How Many Weeks of Adjuvant Herceptin Is Optimal for People with HER2-Positive Breast Cancer?
December 8th 2017A phase 3 clinical trial pitted a nine-week treatment of adjuvant Herceptin against the regimen of a full year of treatment for patients with HER2-positive breast cancer. Results show that the standard treatment of one year is still optimal.
Read More
Controversial Breast Cancer Treatment Strategy May Protect Ovarian Function, Preserve Fertility
December 7th 2017A reveiw of five clinical trial findings suggests that gonadotropin-releasing hormone analog has the potential to preserve ovarian function and fertility in premenopausal breast cancer patients.
Read More
Kisqali Extends Progression-Free Survival for Premenopausal Breast Cancer Subsets
December 7th 2017New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger patients who currently have few treatment options.
Read More
Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes
December 6th 2017For women with early-stage breast cancer who are receiving chemotherapy, shortening the time between treatment cycles or administering the agents sequentially may reduce disease recurrence and mortality compared with standard chemotherapy regimens.
Read More